Basecamp Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$335K Sell
641
-185
-22% -$94.7K 0.08% 133
2026
Q2
$410K Buy
826
+38
+5% +$16.8K 0.08% 148
2026
Q1
$352K Sell
788
-1
-0.1% -$466 0.07% 172
2025
Q4
$358K Buy
+789
New +$340K 0.08% 157

Other funds holding VRTX

Basecamp Wealth Advisors's VRTX Position: Q3 2026 in Review

Basecamp Wealth Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 22% in Q3 2026, selling an estimated $94.7K and leaving 641 shares worth $335K. The position accounts for 0.08% of the portfolio, ranked #133.

Basecamp Wealth Advisors first reported a position in VRTX in Q4 2025 and has held it in 4 quarters since. The position peaked at $410K in Q2 2026. 1,772 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Basecamp Wealth Advisors held 641 shares of Vertex Pharmaceuticals worth $335K as of Q3 2026.
  • Basecamp Wealth Advisors sold 185 Vertex Pharmaceuticals shares in Q3 2026, an estimated $94.7K.
  • Vertex Pharmaceuticals made up 0.08% of Basecamp Wealth Advisors's portfolio in Q3 2026, its #133 holding.
  • Basecamp Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • Basecamp Wealth Advisors's Vertex Pharmaceuticals position peaked at $410K in Q2 2026.
  • 1,772 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.